Cargando…

Developing combinatorial multi-component therapies (CMCT) of drugs that are more specific and have fewer side effects than traditional one drug therapies

Drugs designed for a specific target are always found to have multiple effects. Rather than hope that one bullet can be designed to hit only one target, nonlinear interactions across genomic and proteomic networks could be used to design Combinatorial Multi-Component Therapies (CMCT) that are more t...

Descripción completa

Detalles Bibliográficos
Autores principales: Liebovitch, Larry S, Tsinoremas, Nicholas, Pandya, Abhijit
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2008194/
https://www.ncbi.nlm.nih.gov/pubmed/17908289
http://dx.doi.org/10.1186/1753-4631-1-11
_version_ 1782135865331417088
author Liebovitch, Larry S
Tsinoremas, Nicholas
Pandya, Abhijit
author_facet Liebovitch, Larry S
Tsinoremas, Nicholas
Pandya, Abhijit
author_sort Liebovitch, Larry S
collection PubMed
description Drugs designed for a specific target are always found to have multiple effects. Rather than hope that one bullet can be designed to hit only one target, nonlinear interactions across genomic and proteomic networks could be used to design Combinatorial Multi-Component Therapies (CMCT) that are more targeted with fewer side effects. We show here how computational approaches can be used to predict which combinations of drugs would produce the best effects. Using a nonlinear model of how the output effect depends on multiple input drugs, we show that an artificial neural network can accurately predict the effect of all 2(15 )= 32,768 combinations of drug inputs using only the limited data of the output effect of the drugs presented one-at-a-time and pairs-at-a-time.
format Text
id pubmed-2008194
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-20081942007-10-10 Developing combinatorial multi-component therapies (CMCT) of drugs that are more specific and have fewer side effects than traditional one drug therapies Liebovitch, Larry S Tsinoremas, Nicholas Pandya, Abhijit Nonlinear Biomed Phys Research Drugs designed for a specific target are always found to have multiple effects. Rather than hope that one bullet can be designed to hit only one target, nonlinear interactions across genomic and proteomic networks could be used to design Combinatorial Multi-Component Therapies (CMCT) that are more targeted with fewer side effects. We show here how computational approaches can be used to predict which combinations of drugs would produce the best effects. Using a nonlinear model of how the output effect depends on multiple input drugs, we show that an artificial neural network can accurately predict the effect of all 2(15 )= 32,768 combinations of drug inputs using only the limited data of the output effect of the drugs presented one-at-a-time and pairs-at-a-time. BioMed Central 2007-08-30 /pmc/articles/PMC2008194/ /pubmed/17908289 http://dx.doi.org/10.1186/1753-4631-1-11 Text en Copyright © 2007 Liebovitch et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Liebovitch, Larry S
Tsinoremas, Nicholas
Pandya, Abhijit
Developing combinatorial multi-component therapies (CMCT) of drugs that are more specific and have fewer side effects than traditional one drug therapies
title Developing combinatorial multi-component therapies (CMCT) of drugs that are more specific and have fewer side effects than traditional one drug therapies
title_full Developing combinatorial multi-component therapies (CMCT) of drugs that are more specific and have fewer side effects than traditional one drug therapies
title_fullStr Developing combinatorial multi-component therapies (CMCT) of drugs that are more specific and have fewer side effects than traditional one drug therapies
title_full_unstemmed Developing combinatorial multi-component therapies (CMCT) of drugs that are more specific and have fewer side effects than traditional one drug therapies
title_short Developing combinatorial multi-component therapies (CMCT) of drugs that are more specific and have fewer side effects than traditional one drug therapies
title_sort developing combinatorial multi-component therapies (cmct) of drugs that are more specific and have fewer side effects than traditional one drug therapies
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2008194/
https://www.ncbi.nlm.nih.gov/pubmed/17908289
http://dx.doi.org/10.1186/1753-4631-1-11
work_keys_str_mv AT liebovitchlarrys developingcombinatorialmulticomponenttherapiescmctofdrugsthataremorespecificandhavefewersideeffectsthantraditionalonedrugtherapies
AT tsinoremasnicholas developingcombinatorialmulticomponenttherapiescmctofdrugsthataremorespecificandhavefewersideeffectsthantraditionalonedrugtherapies
AT pandyaabhijit developingcombinatorialmulticomponenttherapiescmctofdrugsthataremorespecificandhavefewersideeffectsthantraditionalonedrugtherapies